Browse > Article
http://dx.doi.org/10.4333/KPS.2003.33.3.209

Preparation and Characterization of Plasmid DNA Encapsulated in Liposomes  

Park, Hyo-Min (College of Pharmacy, Ewha Womans University)
Chung, Soo-Yeon (College of Pharmacy, Ewha Womans University)
Go, Eun-Jung (College of Pharmacy, Ewha Womans University)
Lee, Hwa-Jeong (College of Pharmacy, Ewha Womans University)
Publication Information
Journal of Pharmaceutical Investigation / v.33, no.3, 2003 , pp. 209-213 More about this Journal
Abstract
The objective of this study was to construct the pegylated liposomes containing plasmid DNA with optimal encapsulation efficiency. Plasmid DNA $(pGL2\;clone\;753,\;{\sim}6\;kb)$ was encapsulated by the freeze/thawing method into liposomes composed of 1-palmitoyl-2-oleyl-sn-glycerol-3-phosphocholine (POPC), didodecyl dimethyl ammonium bromide (DDAB), distearoylphosphatidyl ethanolamine polyethylene glycol 2000 (DSPE-PEG 2000) and DSPE-PEG 2000-male-imide. The liposomes containing plasmid DNA were then extruded through two stacked polycarbonate filters with series of different pore sizes to control the liposome size. The plasmid DNA entrapped in the liposomes was separated from free plasmid DNA by Sephadex CL-4B column chromatography. The decreased pore size of polycarbonate filters resulted in the decreased size of liposomes. The encapsulation efficiency was markedly affected by the cationic lipid (DDAB) concentration, but to a low degree by the size of liposomes and by the amount of plasmid DNA.
Keywords
Plasmid DNA; Liposomes; Encapsulation;
Citations & Related Records
연도 인용수 순위
  • Reference
1 E. Galanis, R. Vile and S.J. Russell, Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors, Crit. Rev. Oncol. Hematol.,38, 177-192 (2001)   DOI   ScienceOn
2 A.D. Miller, Retroviral vectors, Curr. Top. Microbial. Immunol., 158, 1-24 (1992)   DOI
3 T.A. Smith, M.G. Mehaffey, D.B. Kayda, J.M. Saunders, S. Yei, B.C. Trapnell, A . McClelland and M. Kaleko, Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice, Nature Genet., 5, 397-402 (1993)   DOI   ScienceOn
4 Y. Setoguchi, H.A. Jaffe, C.-S. Chu and R.G. Crystal, Intraperitoneal in vivo gene therapy to deliver alpha 1-antitrypsin to the systemic circulation, Am. J. Resp. Cell Mol. BioI., 10, 369-377 (1994)   DOI   ScienceOn
5 Y. Yang, F.A. Nunes, K. Berencsi, E.E. Furth, E. Gonczol and J.M. Wilson, Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy, Proc. Natl. Acad. Sci. USA, 91, 4407-4411 (1995)
6 N. Shi and W.M. Pardridge, Noninvasive gene targeting to the brain, Proc. Natl. Acad. Sci. USA, 97, 7567-7572 (2000)   DOI   ScienceOn
7 J. Huwyler, W. Dafang and W.M. Pardridge, Brain drug delivery of small molecules using immunoliposomes, Proc. Natl. Acad. Sci. USA, 93, 14164-14169 (1996)   DOI   ScienceOn
8 P-A. Monnard, T. Oberholzer and P.L. Luisi, Entrapment of nucleic acids in liposomes, Biochim. Biophys. Acta, 1329, 39-50 (1997)   DOI   ScienceOn
9 E.G. Sarabolac, O. Ludkovski, R. Skirrow, M. Ossanlou, Y.P. Zhang, C. Giebrecht, J. Thompson, S. Thomas, H. Stark, P.R. Cullis and P. Scherrer, Encapsulation of plasmid DNA in stabilized plasmid-lipid particles composed of different cationic lipid concentration for optimal transfection activity, J. Drug Target., 7, 423-437 (2000)   DOI   ScienceOn
10 Y. Yang, Q. Li, H.C.J. Erte and J.M. Wilson, Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses, J. Virol., 69, 2004-2015 (1995)
11 D.H. Hamer and P. Leder, Splicing and the formation of stable RNA, Cell, 18, 1299-1302 (1979)   DOI   ScienceOn
12 R.C. Mulligan, B.H. Howard and P. Berg, Synthesis of rabbit beta-globin in cultured monkey kidney cells following infection with a SV40 beta-globin recombinant genome, Nature (London), 277, 108-114 (1979)   DOI   ScienceOn
13 S. Li and L. Huang, Nonviral gene therapy: promises and challenges, Gene Ther., 7, 31-34 (2000)   DOI   ScienceOn
14 A.G. Schatzlein, Non-viral vectors in cancer gene therapy: principles and progress, Anti-Cancer Drugs, 12, 275-304 (2001)   DOI   ScienceOn
15 J. Smith, Y. Zhang and R. Niven, Toward development of a non-viral gene therapeutic, Adv. Drug Deliv. Rev., 26, 135-150 (1997)   DOI   ScienceOn
16 E.R. Kandimalla and S. Agrawal, Antisense Therapeutics: is it as simple as complementary base recognition, Mol. Med. Today, 6, 72-81 (2000)   DOI   ScienceOn
17 K.J. Harrington, E. Linardakis and R.G. Vile, Transcriptional control: an essential component of cancer gene therapy strategies, Adv. Drug Deliv. Rev., 44, 167-184 (2000)   DOI   ScienceOn
18 S. Akhtar, M.D. Hughes, A. Khan, M. Bibby, M. Hussain, Q. Nawaz, J. Double and P. Sayyed, The delivery of antisense therapeutics, Adv. Drug Deliv. Rev., 44, 3-21 (2000)   DOI   ScienceOn
19 S. Akhtar and S. Agrawal, In vivo studies with antisense oligonucleotides, Trends Pharmacal. Sci., 18, 12-18 (1997)   DOI   ScienceOn
20 M. Sioud, Application of preformed hammerhead ribozymes in gene therapy of cancer, Int. J. Mol. Med., 3, 381-384 (1999)
21 D. Sen and C.R. Geyer, DNA enzymes, Curr. Opin. Chem. BioI., 2, 680-687 (1998)   DOI   ScienceOn